DSGN Stock Price, Design Therapeutics, . Quote, Chart

Market Summary

USD3.71+0.06

Market Closed

1.64%

DSGN Alerts

1 major insider buys recently.

DSGN Stock Price

View Fullscreen

DSGN RSI Chart

DSGN Valuation

Market Cap

209.6M

Price/Earnings (Trailing)

-3.13

Price/Sales (Trailing)

647.43

Price/Free Cashflow

-3.56

DSGN Price/Sales (Trailing)

DSGN Profitability

Return on Equity

-24.08%

Return on Assets

-23.08%

Free Cashflow Yield

-28.06%

DSGN Fundamentals

DSGN Revenue

Revenue (TTM)

226.0K

DSGN Earnings

Earnings (TTM)

-66.9M

Earnings Growth (Yr)

31.71%

Earnings Growth (Qtr)

25%

Breaking Down DSGN Revenue

Last 7 days

-1.8%

Last 30 days

0.3%

Last 90 days

55.9%

Trailing 12 Months

-51.1%

How does DSGN drawdown profile look like?

DSGN Financial Health

Current Ratio

29.58

DSGN Investor Care

Shares Dilution (1Y)

0.16%

Diluted EPS (TTM)

-1.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	226.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Design Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	berger heather a.	bought	4,865	3.7429	1,300	-
Mar 25, 2024	schmid john p.	bought	66,605	3.74	17,809	-
Mar 22, 2024	schmid john p.	bought	33,132	3.6187	9,156	-
Sep 29, 2023	lappe rodney w	bought	49,287	2.347	21,000	-
Aug 29, 2023	william arsani	bought	4,782,400	2.44	1,960,000	-
Aug 29, 2023	prasad deepa	bought	27,669	2.3058	12,000	-
Aug 28, 2023	william arsani	bought	591,250	2.15	275,000	-
Dec 20, 2022	george simeon	bought	325,432	8.1358	40,000	-
Dec 20, 2022	sr one capital fund i aggregator lp	bought	325,432	8.1358	40,000	-
Dec 20, 2022	siffert joao md	bought	52,762	8.375	6,300	president and ceo

Which funds bought or sold DSGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	unchanged	-	15,953	46,587	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	new	-	77,732	77,732	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	28.00	28.00	-%
Apr 30, 2024	Private Wealth Management Group, LLC	new	-	2,249	2,249	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	reduced	-17.87	10,040	50,363	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	1.00	4.00	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	155	15,000	20,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-4.59	144,326	464,425	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	41.83	751,758	1,401,610	-%

Are Funds Buying or Selling DSGN?

Are funds buying DSGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DSGN

No. of Funds

DSGN Alerts

1 major insider buys recently.

Unveiling Design Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	3.2%	6	SC 13G/A
Jan 23, 2024	state street corp	1.24%	695,224	SC 13G/A
Nov 14, 2023	ra capital management, l.p.	0%	0	SC 13G/A
Sep 07, 2023	blackrock inc.	4.3%	2,394,544	SC 13G/A
Apr 03, 2023	citadel advisors llc	4.6%	6	SC 13G
Feb 14, 2023	citadel advisors llc	4.4%	6	SC 13G/A
Feb 14, 2023	cormorant asset management, lp	3.09%	1,729,689	SC 13G/A
Feb 08, 2023	state street corp	5.43%	3,037,460	SC 13G
Feb 03, 2023	blackrock inc.	6.3%	3,508,024	SC 13G

Recent SEC filings of Design Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 20, 2024	3	Insider Trading
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Design Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Design Therapeutics, Inc. News

Latest updates

Design Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)				(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	65.0%	33.00	20.00	31.00	142
Operating Expenses	62.0%	3,894	2,403	1,494	765
S&GA Expenses	142.5%	1,186	489	433	388
R&D Expenses	41.5%	2,708	1,914	1,061	377
Interest Expenses	-	6.00	-	-	18.00
Net Income	-66.2%	-3,855	-2,320	-1,442	-663

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-3.4%	290	300	312	325	341	355	368	379	391	400	405	412	37.00
Current Assets	-3.4%	285	295	306	319	335	348	362	374	385	395	405	412	36.00
Cash Equivalents	-24.1%	21.00	28.00	27.00	29.00	27.00	43.00	120	287	299	358	371	401	2.00
Net PPE	-4.9%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00	0.00	0.00	0.00
Liabilities	-19.8%	12.00	15.00	15.00	12.00	14.00	14.00	11.00	8.00	8.00	9.00	4.00	4.00	2.00
Current Liabilities	-22.3%	10.00	12.00	12.00	9.00	11.00	10.00	7.00	5.00	5.00	6.00	3.00	4.00	2.00
Shareholder's Equity	-2.6%	278	285	297	313	327	341	357	370	382	392	402	408	-
Retained Earnings	-7.1%	-177	-165	-149	-130	-110	-93.40	-75.70	-60.72	-47.46	-36.39	-25.07	-17.44	-11.92
Additional Paid-In Capital	0.7%	455	452	449	445	441	438	435	432	430	428	427	425	0.00
Shares Outstanding	0.8%	56.00	56.00	56.00	56.00	56.00	56.00	56.00	56.00	55.00	43.00	55.00	18.00	-
Float	-	-	-	164	-	-	-	373	-	-	-	481	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	11.9%	-12,798	-14,534	-13,804	-17,424	-15,091	-13,899	-10,500	-11,827	-9,227	-8,164	-8,289	-3,697	-2,844	-1,859	-1,307	-2,659
Share Based Compensation	-15.4%	2,724	3,219	3,719	3,426	3,076	2,872	2,617	2,360	1,556	1,243	1,243	647	421	15.00	10.00	4.00
Cashflow From Investing	-63.6%	5,555	15,266	11,982	19,733	-1,056	-63,389	-156,956	414	-50,059	-5,042	-21,571	23,028	1,998	3,187	501	-39,247
Cashflow From Financing	3753.8%	501	13.00	-	-	130	151	-202	156	193	30.00	5.00	378,983	1.00	-	-	44,531

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DSGN Income Statement

2023-12-31

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
Statements of Operations - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development (including related party amounts of $991 and $960, respectively)	$ 57,063	$ 48,613
General and administrative (including related party amounts of $538 and $530, respectively)	21,127	18,980
Total operating expenses	78,190	67,593
Loss from operations	(78,190)	(67,593)
Other income, net	11,328	4,285
Net loss	$ (66,862)	$ (63,308)
Net loss per share, basic	$ (1.19)	$ (1.14)
Net loss per share, diluted	$ (1.19)	$ (1.14)
Weighted-average shares of common stock outstanding, basic	55,984,670	55,707,517
Weighted-average shares of common stock outstanding, diluted	55,984,670	55,707,517

DSGN Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 21,200	$ 26,500
Investment securities	260,598	303,887
Prepaid expenses and other current assets	2,786	4,732
Total current assets	284,584	335,119
Property and equipment, net	1,691	1,947
Right-of-use asset, related party	2,938	3,612
Other assets	430	459
Total assets	289,643	341,137
Current liabilities:
Accounts payable	1,940	3,025
Accrued expenses and other current liabilities (including related party amounts of $716 and $640, respectively)	7,682	7,751
Total current liabilities	9,622	10,776
Operating lease liability, net, related party	2,334	3,051
Total liabilities	11,956	13,827
Commitments and contingencies (See Note 11)
Stockholders' equity:
Common stock: $0.0001 par value; 200,000,000 shares authorized, 56,473,598 and 55,943,314 shares issued, and 56,473,598 and 55,895,596 shares outstanding at December 31, 2023 and 2022, respectively	6	6
Additional paid-in capital	455,245	441,424
Accumulated deficit	(177,626)	(110,764)
Accumulated other comprehensive loss	62	(3,356)
Total stockholders' equity	277,687	327,310
Total liabilities and stockholders' equity	$ 289,643	$ 341,137

About Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

CEO	Mr. Pratik Shah Ph.D.
WEBSITE	designtx.com
INDUSTRY	Biotechnology
EMPLOYEES	68

Design Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Design Therapeutics, Inc.? What does DSGN stand for in stocks?

DSGN is the stock ticker symbol of Design Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Design Therapeutics, Inc. (DSGN)?

As of Fri May 03 2024, market cap of Design Therapeutics, Inc. is 209.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DSGN stock?

You can check DSGN's fair value in chart for subscribers.

What is the fair value of DSGN stock?

You can check DSGN's fair value in chart for subscribers. The fair value of Design Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Design Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DSGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Design Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether DSGN is over valued or under valued. Whether Design Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Design Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DSGN.

What is Design Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, DSGN's PE ratio (Price to Earnings) is -3.13 and Price to Sales (PS) ratio is 647.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DSGN PE ratio will change depending on the future growth rate expectations of investors.